Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study

Autor: Craig, Timothy J *, Levy, Donald S, Reshef, Avner, Lumry, William R, Martinez-Saguer, Inmaculada, Jacobs, Joshua S, Yang, William H, Ritchie, Bruce, Aygören-Pürsün, Emel, Keith, Paul K, Busse, Paula, Feuersenger, Henrike, Alexandru Bica, Mihai, Jacobs, Iris, Pragst, Ingo, Magerl, Markus
Zdroj: In The Lancet Haematology June 2024 11(6):e436-e447
Databáze: ScienceDirect